LY2452473 is an orally bioavailable, selective androgen receptor modulator (SARM). IC50 & Target: Androgen receptor^[1] In Vivo: LY2452473 is a selective androgen receptor modulator being developed for the treatment of disorders related to hypogonadism. LY2452473 is absorbed rapidly (time to reach maximum plasma concentration for both LY2452473 and total radioactivity is 2-3 h) and cleared slowly (plasma terminal t_1/2 of 27 h for LY2452473 and 51 h for the total radioactivity)^[1].